• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

整合素 β3 将治疗抵抗与癌症干细胞特性联系起来。

Integrin β3 links therapy resistance and cancer stem cell properties.

出版信息

Nat Cell Biol. 2014 May;16(5):397-9. doi: 10.1038/ncb2960.

DOI:10.1038/ncb2960
PMID:24914436
Abstract

Heterogeneity in tumour cell properties underlies many treatment failures. Understanding the sources of such heterogeneity has proved to be challenging, but remains critical to improving patient outcomes. Integrin α(v)β₃ expression in multiple types of solid tumour stem cells is now shown to control a pro-survival pathway that contributes to therapy resistance.

摘要

肿瘤细胞特性的异质性是许多治疗失败的基础。事实证明，了解这种异质性的来源具有挑战性，但对于改善患者预后仍然至关重要。现在已经证明，整合素 α(v)β₃在多种实体肿瘤干细胞中的表达可以控制一种促进生存的途径，从而导致对治疗的耐药性。

相似文献

1
Integrin β3 links therapy resistance and cancer stem cell properties.整合素 β3 将治疗抵抗与癌症干细胞特性联系起来。
Nat Cell Biol. 2014 May;16(5):397-9. doi: 10.1038/ncb2960.
2
Targeting the Achilles' heel of drug-resistant cancer stem cells.靶向耐药癌症干细胞的致命弱点。
Cell Cycle. 2014;13(13):2017-8. doi: 10.4161/cc.29460. Epub 2014 Jun 6.
3
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.整合素 β₃-KRAS-RalB 复合物驱动肿瘤干细胞特性和对 EGFR 抑制的抗性。
Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20.
4
Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.整合素介导的对表皮生长因子受体靶向治疗的耐药性：一种炎症状态。
Breast Cancer Res. 2014 Sep 23;16(5):448. doi: 10.1186/s13058-014-0448-0.
5
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.具有获得性 EGFR 抑制剂耐药的肺癌偶尔会发生 BRAF 基因突变，但缺乏 KRAS、NRAS 或 MEK1 突变。
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6.
6
Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.双重靶向 EGFR 和 Neuropilin-1 可减弱 KRAS 突变型非小细胞肺癌对 EGFR 靶向抗体治疗的耐药性。
Cancer Lett. 2019 Dec 1;466:23-34. doi: 10.1016/j.canlet.2019.09.005. Epub 2019 Sep 12.
7
Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.KRAS和RAL在非小细胞肺癌生长和进展中的作用。
J Thorac Oncol. 2013 Dec;8(12):1492-501. doi: 10.1097/JTO.0000000000000007.
8
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.一名对克唑替尼产生获得性耐药的ALK（间变性淋巴瘤激酶）阳性肺腺癌患者同时发生EGFR（表皮生长因子受体）和KRAS（V-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物）突变：病例报告
BMC Res Notes. 2013 Nov 26;6:489. doi: 10.1186/1756-0500-6-489.
9
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.非小细胞肺癌中表皮生长因子受体（EGFR）的激活和耐药性突变：在EGFR酪氨酸激酶抑制剂临床反应中的作用
Oncogene. 2009 Aug;28 Suppl 1(Suppl 1):S24-31. doi: 10.1038/onc.2009.198.
10
Drug Resistance to EGFR Inhibitors in Lung Cancer.肺癌对表皮生长因子受体抑制剂的耐药性
Chemotherapy. 2016;61(5):223-35. doi: 10.1159/000443368. Epub 2016 Feb 25.

引用本文的文献

1
Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway.艾迪注射液通过调节PLAT/FAK/AKT通路抑制吉非替尼耐药肺腺癌细胞的迁移和侵袭。
Chin Med. 2025 Jan 3;20(1):2. doi: 10.1186/s13020-024-01054-1.
2
ITGB3 promotes cisplatin resistance in osteosarcoma tumors.ITGB3 促进骨肉瘤肿瘤对顺铂的耐药性。
Cancer Med. 2023 Apr;12(7):8452-8463. doi: 10.1002/cam4.5585. Epub 2023 Feb 11.
3
Molecular Modeling Insights into the Structure and Behavior of Integrins: A Review.

本文引用的文献

1
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.整合素 β₃-KRAS-RalB 复合物驱动肿瘤干细胞特性和对 EGFR 抑制的抗性。
Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20.
2
The quest to overcome resistance to EGFR-targeted therapies in cancer.克服癌症中表皮生长因子受体靶向治疗耐药性的探索。
Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Epub 2013 Nov 7.
3
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
分子建模对整合素结构与功能的研究进展：综述
Cells. 2023 Jan 14;12(2):324. doi: 10.3390/cells12020324.
4
NUMB suppression by miR-9-5P enhances CD44 prostate cancer stem cell growth and metastasis.miR-9-5P 通过抑制 NUMB 促进 CD44+前列腺癌干细胞的生长和转移。
Sci Rep. 2021 May 27;11(1):11210. doi: 10.1038/s41598-021-90700-x.
5
Hydrogel Scaffolds to Deliver Cell Therapies for Wound Healing.用于伤口愈合细胞疗法的水凝胶支架
Front Bioeng Biotechnol. 2021 May 3;9:660145. doi: 10.3389/fbioe.2021.660145. eCollection 2021.
6
ITGB3/CD61: a hub modulator and target in the tumor microenvironment.整合素β3/CD61：肿瘤微环境中的关键调节因子和靶点
Am J Transl Res. 2019 Dec 15;11(12):7195-7208. eCollection 2019.
7
Molecular chess? Hallmarks of anti-cancer drug resistance.分子棋局？抗癌药物耐药性的特征。
BMC Cancer. 2017 Jan 5;17(1):10. doi: 10.1186/s12885-016-2999-1.
8
Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.实施一项专注于基于肿瘤学的预后和预测结果的精准病理学计划。
Mol Diagn Ther. 2017 Apr;21(2):115-123. doi: 10.1007/s40291-016-0249-5.
9
Microfluidic single-cell transcriptional analysis rationally identifies novel surface marker profiles to enhance cell-based therapies.微流控单细胞转录组分析合理鉴定新型表面标志物谱以增强基于细胞的治疗。
Nat Commun. 2016 Jun 21;7:11945. doi: 10.1038/ncomms11945.
10
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.半乳糖凝集素-1通过激活黏着斑激酶/磷脂酰肌醇-3激酶/蛋白激酶B信号通路诱导肝癌上皮-间质转化和索拉非尼耐药。
Cell Death Dis. 2016 Apr 21;7(4):e2201. doi: 10.1038/cddis.2015.324.
突变 EGFR 相互作用组的扰动可识别脆弱性和耐药机制。
Mol Syst Biol. 2013 Nov 5;9:705. doi: 10.1038/msb.2013.61.
4
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells.通过磷酸化蛋白质组学在肺癌细胞中对 TBK1 信号通路进行解析。
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12414-9. doi: 10.1073/pnas.1220674110. Epub 2013 Jul 8.
5
Cancer stem cells: the challenges ahead.癌症干细胞：未来的挑战。
Nat Cell Biol. 2013 Apr;15(4):338-44. doi: 10.1038/ncb2717.
6
Pushing the limits of targeted therapy in chronic myeloid leukaemia.慢性髓性白血病靶向治疗的极限探索。
Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317.
7
A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.一种针对酪氨酸激酶抑制剂耐药乳腺癌细胞的靶向酶敏化方法。
Exp Cell Res. 2012 Oct 1;318(16):2014-21. doi: 10.1016/j.yexcr.2012.06.001. Epub 2012 Jun 8.
8
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.FLT3 内部串联重复突变在人类急性髓系白血病治疗靶点中的验证。
Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.
9
Cancer stem cells: an evolving concept.癌症干细胞：一个不断发展的概念。
Nat Rev Cancer. 2012 Jan 12;12(2):133-43. doi: 10.1038/nrc3184.
10
A decade of exploring the cancer epigenome - biological and translational implications.一个探索癌症表观基因组的十年 - 生物学和转化意义。
Nat Rev Cancer. 2011 Sep 23;11(10):726-34. doi: 10.1038/nrc3130.